endocrine surgical oncology fall update 2013 - bc cancer · subclinical cushing’s syndrome • a...

31
The Adrenal Incidentaloma Endocrine Surgical Oncology Fall Update 2013 Adrienne Melck, MD, MPH, FRCSC Endocrine and General Surgery St. Paul’s Hospital

Upload: others

Post on 20-Jun-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

The Adrenal Incidentaloma Endocrine Surgical Oncology Fall Update 2013

Adrienne Melck, MD, MPH, FRCSCEndocrine and General Surgery

St. Paul’s Hospital

Page 2: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Outline

Epidemiology

Differential Diagnosis

Clinical Evaluation

Management

Page 3: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Definition

Clinically inapparent adrenal mass detected incidentally with imaging studies conducted for other reasons

Presenter
Presentation Notes
Clinically inapparent or asymptomatic Does not include the scenario where patients are undergoing imaging to stage or follow another primary malignancy
Page 4: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Epidemiology

Overall frequency 4-6%

Prevalence increases with age▫

rare in patients <30yrs▫

~3% of 50-year-olds▫

~7% of 70-year-olds

Incidence increasing

Presenter
Presentation Notes
Overall the incidence is increasing which probably largely has to do with the increased use of imaging and our aging population. Prevalence based on autopsy studies ( Increasingly widespread use of abdominal u/s, ct and MRIs
Page 5: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •
Page 6: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Which adrenal masses require workup?

Any adrenal incidentaloma >1cm should be investigated.

Page 7: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Differential Diagnosis•

Benign or Malignant▫

Adrenocortical carcinoma▫

Metastatic disease

Functioning or Non-functioning▫

Cushing’s syndrome▫

Conn’s syndrome▫

Pheochromocytoma▫

Virilizing/Feminizing tumors

Other▫

Cysts, myelolipomas, ganglioneuromas, hematoma

Page 8: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Differential Diagnosis

Shen et al

82% non-functioning, benign adenomas▫

5% subclinical Cushing’s syndrome▫

5% pheochromocytoma▫

5% adrenocortical carcinoma▫

2.5% metastatic disease▫

1% aldosteronoma

Page 9: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Differential Diagnosis•

Depends on

1.

Size

2.

Patient’s history of malignancy

Page 10: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Adrenal Incidentaloma – Size Matters

Mansmann et al

Page 11: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Adrenal Incidentaloma – Size Matters

Adrenocortical carcinoma

2% tumors ≤4cm

6% tumors 4.1-6cm

25% tumors >6cm

Page 12: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Adrenal Incidentaloma – History of Malignancy

Choyke PL

25-72% chance of mass being a metastasis

10-15% bilateral

lung, melanoma, renal cell, breast, colon

Presenter
Presentation Notes
Depending on the size of the lesion and the type of the primary cancer
Page 13: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Ask yourself 2 questions:

1.

Is the tumor functioning?

2.

Does the tumor have benign imaging characteristics?

Page 14: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

History

Functioning?▫

Hypertension, hypokalemia, muscle cramps, weakness▫

Flushing, diaphoresis, visual disturbance, headaches, tremor, anxiety attacks, palpitations, weight loss

Weight gain, easy bruising, glucose intolerance, fatigue, depression, proximal muscle weakness, osteoporosis, menstrual irregularities, poor wound healing

Malignant?▫

Personal cancer history, constitutional symptoms, local symptoms

Presenter
Presentation Notes
FAMILY HISTORY
Page 15: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Physical Examination•

Functioning?▫

Vital signs: hypertension, tachycardia▫

General appearance: flushed, diaphoretic▫

H & N: moon facies, facial plethora, dorsocervical fat pad, supraclavicular fullness, goiter, hirsutism

Abdomen: truncal obesity, CVA or abdominal tenderness, purple striae, masses

Extremities: thinned skin, peripheral edema, ecchymoses, proximal muscle weakness/wasting

Malignant?▫

General appearance: cachexia▫

Abdomen: masses

Page 16: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Investigations•

All patients should be screened for Cushing’s and pheochromocytoma

Only screen for Conn’s if hypertension

All patients need dedicated adrenal imaging (adrenal protocol CT or MRI)

Myelolipomas don’t need a functional workup

Page 17: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Cushing’s Syndrome

Low dose dexamethasone suppression test▫

Dexamethasone 1mg at 11pm▫

Serum cortisol at 8am

24-hour urine free cortisol▫

4X the normal value diagnostic▫

False positives from anxiety, obesity, smoking, alcoholism

Late-night salivary cortisol▫

earliest and most sensitive marker

Page 18: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Cushing’s Syndrome

No screening tests has 100% sensitivity

If clinical suspicion is high, use >1 test

Once diagnosis made, a low serum ACTH confirms an adrenal source

Page 19: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Subclinical Cushing’s Syndrome

A biochemical diagnosis of Cushing’s syndrome with no overt clinical features

Progression to overt Cushing’s rare

Young et al▫

operate on younger patients <40 years with recent onset or worsening of DM, HTN or osteoporosis

Page 20: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Pheochromocytoma

24-hour urine metanephrines and catecholamines▫

4X normal diagnostic

Plasma free metanephrines▫

High rate of false positives

Ensure patient is not taking any interfering substances

Page 21: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Conn’s Syndrome

Plasma aldosterone and renin levels▫

Collect at 10am and upright for 2 hours▫

Elevated ARR

Do a confirmatory test▫

Saline suppression test

Ensure patient is normokalemic and not on aldosterone antagonists

Page 22: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Conn’s Syndrome

Consider adrenal venous sampling in every patient

Kempers et al▫

systematic review of 950 patients▫

38% patients had discordant imaging and AVS

only CT/MRI inappropriate adrenalectomy in 14.6% inappropriate exclusion of adrenalectomy in 19.1%

Some advocate for AVS only if >40yrs

Page 23: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Summary – Is the tumor functioning?

Order

24-hour urine for metanephrines, catecholamines and free cortisol

low dose dexamethasone suppression test if UFC is elevated

Add aldosterone and renin if patient hypertensive

Routine screening for feminizing/virilizing tumors not necessary

Page 24: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Imaging

Benign adenomas are lipid-rich▫

imaging relies on density measurements

CT Adrenal Protocol▫

Benign: <10 HUs on unenhanced scan, ≥50% contrast washout on delayed scan, smooth borders, homogenous

Atypical

(cancer or pheo): >20 Hus on unenhanced scan, <50% washout on delayed scan, irregular borders, local invasion, central necrosis, size >6cm, heterogeneous

MR Adrenal Protocol▫

Loss of signal on out-of-phase imaging

Presenter
Presentation Notes
Explain what a CT adrenal protocol is Sometimes atypical tumors are just lipid poor adenomas
Page 25: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Benign AdenomaHU <-5, 82% washout

Page 26: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Atypical ImagingHU 54.1, 29% washout

Page 27: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

When to biopsy?

Almost never!

Always exclude pheo first

FNA cannot diagnosis ACC

May be helpful if considering a metastases and definitive diagnosis will alter oncologic treatment planning

Page 28: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

When to operate?

Functioning tumor

Suspicion of malignancy▫

Atypical imaging characteristics▫

Size >4cm▫

Mass growing on serial imaging

Page 29: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

How should I follow benign, non- functioning adenomas?

Repeat imaging at 3-6 months and then annually for 1-2 years▫

5-25% of masses will enlarge in 5 years

Repeat functional workup annually for up to 5 years▫

Up to 20% will become functional, especially if >3cm▫

usually Cushing’s

Page 30: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

Surgical Approaches

Minimally invasive is the gold standard unless suspicion of ACC▫

Laparoscopic transperitoneal▫

Retroperitoneoscopic▫

SILS

Find an experienced surgeon

Page 31: Endocrine Surgical Oncology Fall Update 2013 - BC Cancer · Subclinical Cushing’s Syndrome • A biochemical diagnosis of Cushing’s syndrome with no overt clinical features •

References1.

www.endocrinediseases.org2.

Zeiger

M et al American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the management of adrenal incidentalomas. Endocrine Practice 2009; 15(Suppl 1): 1-20.

3.

Shen

WT et al From incidentaloma

to adrenocortical

carcinoma: the surgical

management of adrenal tumors. J Surg Oncol 2005; 89: 186-92.

4.

Mansmann

et al The clinically inapparent

adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25(2): 309-40.

5.

Choyke

PL ACR appropriateness criteria on incidentally discovered adrenal mass. J Am Coll Radiol 2006; 3: 498-504.

6.

Young WF The incidentally discovered adrenal mass. NEJM 2007; 356(6): 601-10.7.

Kempers

et al Systematic review: diagnostic procedures to differentiate

unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151(5):329-37.